The Importance of Antiviral Prophylaxis against Hepatitis B Virus in Patients under Immunosuppressive Therapy

AKSOY F., KAYA S., Karakoc H. N., YILMAZ G., Atalar S., Koksal I.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, vol.25, no.2, pp.50-54, 2019 (ESCI) identifier


Objectives: Immunosuppressive (IS) therapies present a risk of reactivation in patients with previous or known hepatitis B virus (HBV) infection and may cause mortality and morbidity. Before starting these therapies, patients should be tested for HBV serology and evaluated for antiviral therapy.